HC Wainwright Issues Negative Outlook for VNDA Earnings
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Free Report) – Research analysts at HC Wainwright cut their Q1 2025 EPS estimates for Vanda Pharmaceuticals in a note issued to investors on Tuesday, February 18th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will earn ($0.52) per share for the quarter, down from their prior […]
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Free Report) – Research analysts at HC Wainwright cut their Q1 2025 EPS estimates for Vanda Pharmaceuticals in a note issued to investors on Tuesday, February 18th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will earn ($0.52) per share for the quarter, down from their prior […]
